• Emergent BioSolutions Inc EBS.N reported quarterly adjusted earnings of $1.06​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $1.37. The mean expectation of three analysts for the quarter was for a loss of 12 cents per share. to range from -35 cents to 11 cents per share.

• Revenue fell 23.6% to $231.10 million from a year ago; analysts expected $194.00 million.

• Emergent BioSolutions Inc's reported EPS for the quarter was a loss of $1.04​.

• The company reported a quarterly loss of $54.6 million.

• Emergent BioSolutions Inc shares had fallen by 10.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 191.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 17.8% above its last closing price of $11.10

This summary was machine generated from LSEG data February 26 at 11:24 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)